Language
English
Publication Date
1-1-2024
Journal
Antimicrobial Stewardship & Healthcare Epidemiology
DOI
10.1017/ash.2024.81
PMID
38807931
PMCID
PMC11131004
PubMedCentral® Posted Date
5-22-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and Clostridioides difficile (CDI) between time periods of levofloxacin prophylaxis implementation. Benefits were sustained without increasing MDRO or CDI.
Published Open-Access
yes
Recommended Citation
Davis, Andrea L; Stevens, Alexandra M; Brackett, Julienne; et al., "Levofloxacin Prophylaxis for Pediatric Leukemia Patients: Monitoring of Outcomes for Sustained Benefit and Consequences" (2024). Faculty and Staff Publications. 3374.
https://digitalcommons.library.tmc.edu/baylor_docs/3374
Included in
Hematology Commons, Hemic and Lymphatic Diseases Commons, Infectious Disease Commons, Medical Sciences Commons, Oncology Commons, Pediatrics Commons